What the July 2026 PCAC meeting could change

The Pharmacy Compounding Advisory Committee meets this July in a session that will likely shape which peptides can legally be prescribed through licensed pharmacies — and which remain off the list.

Update, September 14, 2026: The committee met on July 23–24, 2026, and reviewed seven peptides. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Most of this article is a preview first written in April 2026.

TL;DR

• The FDA's Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory body whose recommendations inform the FDA's decisions on which compounds may be used in 503A compounding.
• The July 23–24, 2026 PCAC meeting reviewed seven peptides for the Section 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. The committee voted to recommend all of them except emideltide (DSIP).
• A PCAC recommendation is not an FDA decision — the agency can accept, modify, or decline a committee recommendation. Adding a peptide to the bulks list also requires subsequent Federal Register rulemaking before it becomes effective. As of September 14, 2026, FDA has not made a final decision.

What it is

The Pharmacy Compounding Advisory Committee is an FDA advisory committee established under the Federal Advisory Committee Act to provide independent expert advice on issues related to the compounding of drugs. PCAC members include pharmacists, physicians, patient advocates, and regulatory scientists. The committee evaluates nominated bulk drug substances — the raw materials used in compounding — and provides recommendations to the FDA on whether they should be eligible for use under Section 503A or 503B. PCAC does not have regulatory authority itself; its recommendations are advisory, and the FDA retains final decision-making authority.

How it works

The PCAC review process for a nominated substance follows a defined sequence. The FDA staff prepares a briefing document summarizing the available data on a nominated compound's safety, effectiveness, and clinical need. PCAC members review this document in advance of the meeting, then hold an open public session where the data is presented and discussed. The public may submit written comments through the docket, and nominated speakers may address the committee. At the end of the session, the committee votes on a recommendation: typically "should be eligible," "should not be eligible," or "defer for additional information." That recommendation is then transmitted to the FDA Commissioner's office, which uses it — alongside other data and policy considerations — to make a final determination.

Who asks about it

People come to this topic after following Secretary Kennedy's February 2026 remarks and FDA's April 2026 category change, and wanting to understand the next concrete procedural step. The July 2026 meeting was that step for the seven peptides on its agenda. Physicians, pharmacy operators, and informed patients tracked this date because the outcome will shape which of these peptides FDA adds to the 503A bulks list.

What the research says

Before the meeting, FDA staff briefing documents recommended against adding the peptides. The agenda listed seven peptides, each for specific uses. For these seven peptides, the key question before the committee was whether the available safety data — including newer pre-clinical studies and any human safety data that has emerged since FDA placed them in Category 2 in 2023 — was sufficient to support adding them to the 503A bulks list. The vote was not a foregone conclusion in either direction.

What to know before considering it

The July 2026 PCAC meeting was a necessary procedural step, not a guaranteed outcome. Even a favorable PCAC vote does not immediately add the named peptides to the 503A bulks list — Federal Register publication and rulemaking still follow. Halftime Health will update its clinical formulary and content as formal regulatory changes take effect.

The Halftime POV

PCAC meetings are one of the more transparent moments in the drug regulation process — the briefing documents are public, the meeting is open, and the vote is on the record. That makes them genuinely useful for anyone who wants to understand where the regulatory process is heading. We followed the July 2026 meeting closely, and this article now includes the committee's recommendations.

---

Related reading:

• Category 1 Vs Category 2
• Rfk Peptide Reclassification
• Bpc 157 Category 2

FAQ

Q: What is the Pharmacy Compounding Advisory Committee (PCAC)? A: PCAC is an FDA advisory committee that reviews bulk drug substances nominated for use in compounding under Section 503A. It evaluates clinical evidence, safety data, and the need for compounded access for nominated substances. PCAC recommendations inform but do not determine FDA's final category decisions — the FDA makes the ultimate regulatory call.

Q: What happened at the July 2026 PCAC meeting? A: FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026. It reviewed seven peptides for the Section 503A bulk drug substances list. On July 23, it voted to recommend adding BPC-157, KPV, TB-500, and MOTS-c. On July 24, it voted to recommend adding Semax and Epitalon, and it voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

Q: How can the public participate in PCAC meetings? A: PCAC meetings are public. The FDA announces meeting dates, agendas, and registration procedures on FDA.gov. Public comments can be submitted in advance through dockets open for each nominated substance. Physicians, patient advocates, researchers, and members of the public have submitted comments on the peptides under review.

---

Disclaimer

Several peptides discussed in this article — including KPV, MOTS-c, DSIP, epitalon, and Semax — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA. Pharmacy Compounding Advisory Committee. Meeting dates and materials. FDA.gov
• FDA. "Bulk Drug Substances That May Be Used in Compounding Under Section 503A." FDA.gov
• Federal Advisory Committee Act. 5 U.S.C. App. 2
• Robert F. Kennedy Jr., HHS Secretary. Remarks on peptides, The Joe Rogan Experience podcast, February 27, 2026. HHS issued no press release or Federal Register notice.

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.